Premarket Movers Oct 5, 2026: MI, BEAT, ALEC

MI — NFT Ltd (+249.1%)

NFT Ltd is soaring 249.1% in premarket trading this morning, hitting $3.05 on 17,785,694 shares — an extraordinary 210× its 20-day average volume of 84,692. That kind of liquidity explosion in a stock with a $3.0M market cap almost always signals speculative momentum rather than fundamental news, and this morning is no exception.

Why it's moving: No clear fundamental catalyst is present in the available data. The recent headlines attributed to "MI" are unrelated financial data pages referencing the Milan stock exchange ticker suffix (.MI), not NFT Ltd itself. The SEC filings — two neutral 6-Ks and a Schedule 13G/A — contain no disclosed material event. With no researched catalyst to lead with, this move looks purely momentum- and technically-driven, likely fueled by retail attention and extreme low-cap volatility.

The float and squeeze read: A short-sale restriction (SSR) is already active, meaning regulators have flagged elevated downward price pressure — ironically, SSR can temporarily squeeze short sellers and amplify upside spikes. Short interest is tiny at just 36,889 shares (0.1 days to cover), so this isn't a classic short squeeze. The squeeze score is a low 6/100. The real fuel here appears to be the paper-thin $3.0M market cap: it takes very little buying to move the stock a dramatic percentage.

Technical picture: The prior-day chart carried a deeply bearish setup — RSI of 20 (deeply oversold territory), a bearish MA stack, and a score of 1 on both RS rating and technical rank. The stock sat 99.8% below its 52-week high. StockSetups assigned a conviction score of 0/100 and a D grade going into this morning. Moves like this from deeply oversold, ultra-micro-cap names can reverse violently once premarket volume fades. Treat this as high-risk speculation.

BEAT — HeartBeam, Inc. (+88.2%)

HeartBeam is trading up 88.2% to $0.82 in premarket action, with 67,906,828 shares already changing hands — roughly 140× its 20-day average of 484,804. For a healthcare micro-cap with a $24.5M market cap, that's a genuine volume surge with a clear fundamental reason behind it.

Why it's moving: HeartBeam received an FDA Breakthrough Device Designation for its heart attack assessment technology, according to Yahoo Finance and Stock Titan this morning. The FDA's Breakthrough Device program is designed to speed up development and review of medical devices that treat serious conditions — in this case, assessing suspected heart attacks outside of a hospital setting. That's a meaningful regulatory milestone for a small-cap medtech company and is the direct driver of this morning's spike.

Short squeeze dynamics: BEAT carries a squeeze score of 41/100 — moderate, but worth noting. Short interest stands at 1,941,356 shares with 6.4 days to cover (meaning, at average volume, it would take shorts 6.4 days of buying to close their positions). When a strong catalyst hits a stock with that kind of short interest, trapped short sellers are forced to buy to limit losses, which amplifies the upward move. That's the mechanics of a short squeeze layered on top of the FDA news.

Technical picture: The prior-day chart showed a bearish MA stack and a stock sitting 87.3% below its 52-week high. RSI was a neutral 52, and StockSetups rated BEAT with a conviction score of 0/100 and a D grade heading into today — standard for a name that had been in a prolonged downtrend. The premarket gap is built on real news, but BEAT was deeply distressed technically before this morning. Big gaps on small-cap biotech news are notorious for partial reversals once the regular session opens and early buyers take profits.

APUS — Apimeds Pharmaceuticals US, Inc. (+67.1%)

Apimeds Pharmaceuticals is up 67.1% to $5.28 premarket, trading 18,754,634 shares against a 20-day average of 6,483,305 — about 2.9× normal, elevated but far more moderate than the names above. With a $4.8M market cap, APUS falls into the highly speculative micro-cap category where even modest dollar flows can produce outsized percentage moves.

Why it's moving: No hard fundamental catalyst is evident from the available data. The most recent SEC filing is a neutral 8-K from October 1 flagging a management change — the appointment of Eric Sherb as the new CFO. The headline from timothysykes.com describes APUS as "whipsawing as traders target extreme volatility," which aligns with a momentum- and technically-driven interpretation rather than a single news event. The stock has appeared in prior StockSetups recaps — it was a top mover in late September as well — suggesting a pattern of recurring speculative activity.

Float and squeeze read: The free float is 54.4% with a short-sale restriction (SSR) active. Short interest is minimal at 19,919 shares (0.1 days to cover), so short covering isn't the engine here. The squeeze score is just 8/100. The SSR flag tells you the stock was already under selling pressure before this morning's spike. With a bearish prior-day candle (a bearish marubozu — a candlestick with little to no wicks, indicating sellers controlled the entire session), the premarket surge looks like a whipsaw continuation of volatile two-way trading.

Technical picture: RSI sat at a neutral 46 on the prior-day chart, ADX at 31 (trending but not strongly directional), and the MA stack was bearish. StockSetups had APUS at a conviction score of 2/100, grade D, and a trend-template score of 1/5 — no real technical base to speak of. The stock is 91% below its 52-week high.

VEEA — VEEA INC. (+62.7%)

VEEA Inc. is up 62.7% to $5.40 premarket, with 29,606,019 shares traded against a 20-day average of 17,516,217 — roughly 1.7× normal. At a $206.6M market cap, VEEA is the largest name on today's premarket list and has appeared repeatedly in recent StockSetups recaps, including after-hours on October 2 and as a top mover on October 1.

Why it's moving: The most recent material development from the data is a $1.65 million insider loan announced October 2: an affiliate of the CEO extended four unsecured demand notes to VEEA at a 10% interest rate for working capital purposes, per TradingView, Stock Titan, and a filed 8-K. Unsecured demand notes are a form of short-term debt that can be called back at any time — this is a company borrowing from insiders to keep the lights on, which is typically a sign of financial stress rather than strength. That said, the premarket action may be partly driven by renewed retail attention and momentum from the prior week's volatile price action.

Short squeeze angle: VEEA's free float is a relatively tight 43.5%, with 671,095 shares short and 2.8 days to cover. The SSR is active. The squeeze score is 20/100 — low, but the limited float means the stock can move sharply on relatively small order flow. A low float means fewer shares are available to trade in the open market, which amplifies price swings in both directions.

Technical picture: The prior-day chart showed a mixed MA stack (some moving averages above price, some below), RSI of 53, and an ADX of 39 — indicating the stock was in a trending state. StockSetups rated VEEA at conviction 18/100, grade D, and a trend-template score of 2/5. That's marginally better than others on today's list, but still well below any technical breakout standard.

ALEC — Alector, Inc. (+60.4%)

Alector is up 60.4% to $2.92 in premarket trading, on 46,259,138 shares versus a 20-day average of 1,357,021 — a massive 34× surge in volume. At a $203.2M market cap, ALEC is the second-largest name on this morning's list and, unlike the others, has a concrete, substantial catalyst.

Why it's moving: Alector has licensed its AL050 GCase program to Genentech (a member of the Roche Group), with the deal carrying potential milestone payments of up to $1.17 billion if future development and commercial goals are met, according to Stock Titan and TipRanks. The GCase program is related to Parkinson's disease research. For a company with a $203M market cap, a potential $1.17B milestone-laden licensing deal with a major pharma partner is a transformative event — this is the real catalyst. Additionally, a new Schedule 13G passive stake filing has drawn additional trader attention, per headlines from timothysykes.com and StocksToTrade. A Schedule 13G indicates a new institutional or passive investor has crossed the 5% ownership threshold.

Short squeeze potential: ALEC has the highest squeeze score on today's list at 54/100 — a meaningful reading. Short interest is 6,165,227 shares with 4.6 days to cover, and short-volume was running at 65% of prior-day volume. When a legitimate catalyst hits a stock with this level of short positioning, short sellers face mounting losses and may be forced to cover (buy shares to close their positions), adding fuel to the rally. This is a genuine squeeze setup layered on top of a licensing announcement.

Technical picture: The prior-day chart showed a mixed MA stack, RSI of 39 (slightly oversold), and ADX of 21. ALEC sits 45.2% below its 52-week high — a smaller deficit than most others on today's list, suggesting it hadn't fallen as far. StockSetups rated it conviction 24/100 (highest on today's list), grade D, trend-template 3/5, and a smart-money score of 16/100 with a largest disclosed stake of 8.4%. The new passive stake filing adds to that smart-money narrative, though the stock is still technically recovering rather than breaking out.

The bottom line

This morning's premarket list spans the full risk spectrum — from a catalyst-free micro-cap moonshot (MI) to a substantive pharma licensing deal (ALEC) and a genuine FDA regulatory milestone (BEAT). The common thread: every one of these stocks carries meaningful risk before the regular session even opens.

Premarket moves happen on lighter volume than regular hours, which means prices can shift sharply when the 9:30 AM ET open arrives and a broader pool of buyers and sellers enters the market. Stocks that look like they're holding large gains premarket frequently give back a significant portion — or all — of those gains by the close. Big one-day gainers can reverse just as fast, and short squeezes can unwind abruptly once short sellers finish covering.

Pattern setups, squeeze scores, and FDA catalysts are useful context — but they are not guarantees. Chasing any of these names after a 60–249% premarket move is high-risk by definition. Always size positions with the possibility of a full reversal in mind, and do your own research before acting.

StockSetups scans the full ~12,300-stock US universe every premarket morning — detecting chart patterns, computing squeeze and conviction scores, and surfacing names like these before the open. Check back after today's close for the full regular-session recap.